Be the first to like this
Following a recent trend of pharmaceutical giants buying smaller companies for a specific product that shows potential, Amgen Inc. purchased Onyx Pharmaceuticals in late 2013. The $10.4 billion deal gives Amgen a presence in the cancer drug market, as it obtained the multiple myeloma drug Kyprolis in the transaction. The sale values Onyx at $125 a share, more than four times the price at which the stock traded five years ago.
Clipping is a handy way to collect important slides you want to go back to later.